- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02365597
Un estudio de eficacia y seguridad de erdafitinib (JNJ-42756493) en participantes con cáncer urotelial
Un estudio de fase 2, multicéntrico, abierto, de dos brazos para determinar la eficacia y la seguridad de dos regímenes de dosis diferentes de un inhibidor de la tirosina quinasa Pan-FGFR JNJ-42756493 en sujetos con cáncer urotelial metastásico o irresecable quirúrgicamente con alteraciones genómicas de FGFR
The purpose of this study is to evaluate the objective response rate (complete response [CR]+ partial response [PR]) of the selected dose regimen in participants with metastatic or surgically unresectable urothelial cancers that harbor specific FGFR genomic alterations.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is a multicenter, open-label study (participants will know the identity of study drugs administered) to evaluate the efficacy and safety of erdafitinib in participants with urothelial cancer. The study comprises a 30-days Screening Phase, a Treatment Phase comprised of 28-day treatment cycles that will continue until disease progression or unacceptable toxicity occurs in a long-term extension (LTE) phase, and a post-treatment Follow-up Phase that will extend from the End-of-Treatment Visit until the participant has died, withdraws consent, is lost to follow-up, or the end of the study, whichever comes first. The end of study is defined as the date when all participants have completed the study treatment (Regimens 1 to 3) and all participants enrolled under the drug-drug interaction (DDI) substudy are no longer receiving treatment with erdafitinib. The purpose of DDI sub-study is to evaluate the interaction of repeated doses of erdafitinib with a sensitive cytochrome 450 (CYP) 3A substrate (midazolam) and with an organic cation transporter 2 (OCT2) probe substrate (metformin). Safety will be monitored throughout the study.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Acceso ampliado
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Berlin, Alemania
-
Erlangen, Alemania
-
Essen, Alemania
-
Freiburg im Breisgau, Alemania
-
Greifswald, Alemania
-
Göttingen, Alemania
-
Hamburg, Alemania
-
Hanover, Alemania
-
Heidelberg, Alemania
-
München, Alemania
-
Münster, Alemania
-
Regensburg, Alemania
-
Straubing, Alemania
-
Weiden/Opf, Alemania
-
-
-
-
-
Graz, Austria
-
Linz, Austria
-
Vienna, Austria
-
-
-
-
-
Aalst, Bélgica
-
Brussels, Bélgica
-
Charleroi, Bélgica
-
Ghent, Bélgica
-
Wilrijk, Bélgica
-
-
-
-
-
Daejeon, Corea del Sur
-
Goyang-si, Corea del Sur
-
Incheon, Corea del Sur
-
Seoul, Corea del Sur
-
-
-
-
-
Badalona, España
-
Barcelona, España
-
Madrid, España
-
Málaga, España
-
Pamplona, España
-
Sabadell, España
-
Santander, España
-
Santiago de Compostela, España
-
Seville, España
-
Valencia, España
-
-
-
-
Arizona
-
Sedona, Arizona, Estados Unidos
-
-
California
-
Los Angeles, California, Estados Unidos
-
Orange, California, Estados Unidos
-
Sacramento, California, Estados Unidos
-
Stanford, California, Estados Unidos
-
-
Colorado
-
Aurora, Colorado, Estados Unidos
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos
-
-
Illinois
-
Chicago, Illinois, Estados Unidos
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos
-
-
New York
-
New York, New York, Estados Unidos
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos
-
-
Oregon
-
Medford, Oregon, Estados Unidos
-
Tualatin, Oregon, Estados Unidos
-
-
Pennsylvania
-
Hershey, Pennsylvania, Estados Unidos
-
Pittsburgh, Pennsylvania, Estados Unidos
-
-
South Carolina
-
Myrtle Beach, South Carolina, Estados Unidos
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos
-
-
Texas
-
Dallas, Texas, Estados Unidos
-
Denton, Texas, Estados Unidos
-
Houston, Texas, Estados Unidos
-
-
Virginia
-
Hampton, Virginia, Estados Unidos
-
-
-
-
-
Angers, Francia
-
Bordeaux, Francia
-
Caen Cédex 05, Francia
-
Dijon, Francia
-
Lyon, Francia
-
Nice, Francia
-
Nîmes, Francia
-
Paris, Francia
-
Saint-Herblain, Francia
-
Suresnes, Francia
-
Villejuif, Francia
-
-
-
-
-
Bangalore, India
-
Kolkata, India
-
Mira Road (East), India
-
Nadiād, India
-
-
-
-
-
Beer Yaakov, Israel
-
Beersheba, Israel
-
Haifa, Israel
-
Kfar Saba, Israel
-
Petah Tikva, Israel
-
Tel Aviv, Israel
-
-
-
-
-
Chisinau, Moldava
-
-
-
-
-
Blackburn, Reino Unido
-
Dundee, Reino Unido
-
Essex, Reino Unido
-
London, Reino Unido
-
Metropolitan Borough of Wirral, Reino Unido
-
Plymouth, Reino Unido
-
Sutton, Reino Unido
-
-
-
-
-
Bucharest, Rumania
-
Cluj-Napoca, Rumania
-
Craiova, Rumania
-
Iași, Rumania
-
-
-
-
-
Barnaul, Rusia
-
Moscow, Rusia
-
Omsk, Rusia
-
Pyatigorsk, Rusia
-
Saint Petersburg, Rusia
-
Ufa, Rusia
-
-
-
-
-
Taichung, Taiwán
-
Tainan, Taiwán
-
Taipei, Taiwán
-
Taoyuan, Taiwán
-
-
-
-
-
Istanbul, Turquía (Türkiye)
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Must have histologic demonstration of metastatic or surgically unresectable urothelial cancer. Minor components of variant histology such as glandular or squamous differentiation, or evolution to more aggressive phenotypes such as sarcomatoid or micropapillary change are acceptable
- Must have measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) at baseline
- Must have an Eastern Cooperative Oncology Group (ECOG) performance status score 0, 1, or 2
- Must have adequate bone marrow, liver, and renal function as described in protocol
- Negative pregnancy test (urine or serum beta human chorionic gonadotropin [b-hCG]) at Screening for women of child bearing potential who are sexually active
- Must have shown disease progression according to RECIST, version 1.1, following prior chemotherapy for metastatic or surgically unresectable urothelial cancer. Participants who received neoadjuvant or adjuvant chemotherapy and showed disease recurrence or progression according to RECIST, version 1.1, within 12 months of the last dose are considered to have received chemotherapy in the metastatic setting. These participants will be referred to as chemo-refractory participants. (Participants who have shown disease progression according to RECIST, version 1.1 following prior treatment with anti-Programmed death-ligand 1 (anti PDL1/PD1) antibodies are also eligible) For DDI substudy
- Disease progression following prior chemotherapy for metastatic or surgically unresectable urothelial cancer. Participants who received neoadjuvant or adjuvant chemotherapy and showed disease recurrence or progression within 12 months of the last dose are considered to have received chemotherapy in the metastatic setting
Exclusion Criteria:
- Received chemotherapy, targeted therapies, definitive radiotherapy, or treatment with an investigational anticancer agent within 2 weeks (in the case of nitrosoureas and mitomycin C, within 6 weeks; in the case of immunotherapy, within 4 weeks) before the first administration of study drug. Localized palliative radiation therapy (but should not include radiation to target lesions) and ongoing bisphosphonates and denosumab, are permitted
- Has persistent phosphate level greater than upper limit of normal (ULN) during screening (within 14 days of treatment and prior to Cycle 1 Day 1) and despite medical management
- Has a history of or current uncontrolled cardiovascular disease
- Females who are pregnant, breast-feeding, or planning to become pregnant within 3 months after the last dose of study drug and males ho plan to father a child while enrolled in this study or within 5 months after the last dose of study drug
- Has not recovered from reversible toxicity of prior anticancer therapy (except toxicities which are not clinically significant such as alopecia, skin discoloration, or Grade 1 neuropathy)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Erdafitinib (8 milligram)
Prior to interim analysis 1 (IA1), there were 2 treatment regimens: Regimen 1 (10 milligram [mg] once daily, 7 days on/7 days off); and Regimen 2 (6 mg once daily for 28 days). Following IA1, Regimen 1 is closed for further enrollment and starting dose of Regimen 2 is increased to 8 mg once daily for 28 days on a 28-day cycle (referred to as Regimen 3). Participants who enrolled in DDI substudy will receive pretreatment with single doses of midazolam (Day -2) and metformin (Day -1). Participants enrolled in DDI substudy will receive 8 mg erdafitinib treatment from Day 1 to Day 15, single doses of midazolam 2.5 mg (Day 13) and metformin 1000 mg (Day 14) and erdafitinib treatment will continued until disease progression. Participants who completed the DDI substudy and continue to benefit from erdafitinib treatment, will continue to receive erdafitinib in long-term extension (LTE) phase. |
8 mg orally once daily for 28 days on a 28 day cycle.
Otros nombres:
Participants who enrolled in DDI substudy will receive pretreatment with single dose of midazolam on Day -2 and single dose of midazolam on Day 13. Participants who enrolled in DDI substudy will receive pretreatment with single dose of metformin on Day -1 and single dose of metformin on Day 14. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Main Study: Percentage of Participants With Best (Overall) Objective Response
Periodo de tiempo: From Cycle 1 Day 1 up to 6 years 2 months
|
Percentage of participants with best (overall) objective response were reported. Best objective response is defined as the best (overall) objective response a participants achieved during the study in the order of complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), where CR and PR were confirmed as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. As per RECIST version 1.1, CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in the short axis to less than (<) 10 millimeters (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Responders are participants with BOR of CR or PR. |
From Cycle 1 Day 1 up to 6 years 2 months
|
|
Drug-Drug Interaction (DDI) Substudy: Maximum Observed Plasma Concentration (Cmax) of Midazolam Alone or in Combination With Erdafitinib
Periodo de tiempo: Cycle 1 Day -2 (predose) up to Day 13 post dose
|
Cmax is the maximum observed plasma concentration of midazolam alone or in combination with erdafitinib. |
Cycle 1 Day -2 (predose) up to Day 13 post dose
|
|
Drug-Drug Interaction (DDI) Substudy: Maximum Observed Plasma Concentration (Cmax) of 1-OH-Midazolam (Midazolam Metabolite) Alone or in Combination With Erdafitinib
Periodo de tiempo: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
|
Cmax is the maximum observed plasma concentration of 1-OH-Midazolam (midazolam metabolite) alone or in combination with erdafitinib. |
Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
|
|
Drug-Drug Interaction (DDI) Substudy: Maximum Observed Plasma Concentration (Cmax) of Metformin Alone or in Combination With Erdafitinib
Periodo de tiempo: Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)
|
Cmax is the maximum observed plasma concentration of metformin alone or in combination with erdafitinib |
Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)
|
|
Drug-Drug Interaction (DDI) Substudy: Time to Reach the Maximum Observed Plasma Concentration (Tmax) of Midazolam Alone or in Combination With Erdafitinib
Periodo de tiempo: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
|
Tmax is the time to reach the maximum observed plasma concentration of midazolam alone or in combination with erdafitinib. |
Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
|
|
Drug-Drug Interaction (DDI) Substudy: Time to Reach the Maximum Observed Plasma Concentration (Tmax) of 1-OH-Midazolam (Midazolam Metabolite) Alone or in Combination With Erdafitinib
Periodo de tiempo: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
|
Tmax is the time to reach the maximum observed plasma concentration of 1-OH-Midazolam alone or in combination with erdafitinib. |
Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
|
|
Drug-Drug Interaction (DDI) Substudy: Time to Reach the Maximum Observed Plasma Concentration (Tmax) of Metformin Alone or in Combination With Erdafitinib
Periodo de tiempo: Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)
|
Tmax is the time to reach maximum observed plasma concentration of metformin alone or in combination with erdafitinib |
Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)
|
|
Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC[0-last]) of Midazolam Alone or in Combination With Erdafitinib
Periodo de tiempo: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
|
AUC(0-last) is the area under the plasma concentration versus time curve from time 0 to the time of the last measurable concentration of midazolam alone or in combination with erdafitinib. |
Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
|
|
Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC[0-last]) of 1-OH-Midazolam (Midazolam Metabolite) Alone or in Combination With Erdafitinib
Periodo de tiempo: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
|
AUC(0-last) is the area under the plasma concentration versus time curve from time 0 to the time of the last measurable concentration of 1-OH-Midazolam alone or in combination with erdafitinib. |
Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
|
|
Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC[0-last]) of Metformin Alone or in Combination With Erdafitinib
Periodo de tiempo: Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)
|
AUC(0-last) is the area under the plasma concentration versus time curve from time 0 to the time of the last measurable concentration of metformin alone or in combination with erdafitinib. |
Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)
|
|
Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Infinite Time (AUC[0-Infinity]) of Midazolam Alone or in Combination With Erdafitinib
Periodo de tiempo: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
|
AUC(0-Infinity) is the area under the plasma concentration versus time curve from time 0 to the infinite time of midazolam alone or in combination with erdafitinib. |
Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
|
|
Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Infinite Time (AUC[0-Infinity]) of 1-OH-Midazolam (Midazolam Metabolite) Alone or in Combination With Erdafitinib
Periodo de tiempo: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
|
AUC(0-Infinity) is the area under the plasma concentration versus time curve from time 0 to the infinite time of 1-OH-Midazolam alone or in combination with erdafitinib. |
Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
|
|
Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Infinite Time (AUC[0-Infinity]) of Metformin Alone or in Combination With Erdafitinib
Periodo de tiempo: Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)
|
AUC(0-Infinity) is the area under the plasma concentration versus time curve from time 0 to the infinite time of metformin alone or in combination with erdafitinib |
Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Main Study: Progression-free Survival (PFS)
Periodo de tiempo: From screening up to 6 years 2 months
|
Progression-free survival is defined as the duration from the date of the first dose of study drug until the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death due to any cause, whichever occurs first, regardless of the use of subsequent anticancer therapy. As per RECIST version 1.1, CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in the short axis to less than (<) 10 millimeters (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. |
From screening up to 6 years 2 months
|
|
Main Study: Duration of Response (DoR)
Periodo de tiempo: From screening up to 6 years 2 months
|
DOR is defined as the time (in months) from the date of first observation of response (PR or CR) to the date of the first observation of progression or date of death, whatever the cause based on the RECIST version 1.1. CR: disappearance of all target and non-target lesions. All pathological (whether target or non-target) must have a reduction in their short axis <10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD was defined as at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. |
From screening up to 6 years 2 months
|
|
Main Study: Overall Survival
Periodo de tiempo: From screening up to 6 years 2 months
|
Overall survival is defined as the time from the date of first dose of study drug to the date of the participant's death from any cause. |
From screening up to 6 years 2 months
|
|
Main Study: Percentage of Participants With Treatment-emergent Adverse Event (TEAEs)
Periodo de tiempo: From Day 1 up to 6 years 2 months
|
Percentage of participants with TEAEs were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are those events that occurred from first dose date through 30 days after last dose date, or day before subsequent anticancer therapy, whichever occurs first. |
From Day 1 up to 6 years 2 months
|
|
Main Study: Plasma Concentration of Erdafitinib at 2 Hours (C2h)
Periodo de tiempo: Cycle 1 Days 1 and 21: Pre-dose up to 2 hours post-dose (each cycle length=28 days)
|
C2h is the plasma concentration of erdafitinib at 2 hours. |
Cycle 1 Days 1 and 21: Pre-dose up to 2 hours post-dose (each cycle length=28 days)
|
|
Main Study: Plasma Concentration of Erdafitinib at 4 Hours (C4h)
Periodo de tiempo: Cycle 1 Days 1 and 21: Pre-dose up to 4 hours post-dose (each cycle length=28 days)
|
C4h is the plasma concentration of erdafitinib at 4 hours. |
Cycle 1 Days 1 and 21: Pre-dose up to 4 hours post-dose (each cycle length=28 days)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Publicaciones y enlaces útiles
Publicaciones Generales
- Siefker-Radtke AO, Necchi A, Park SH, Garcia-Donas J, Huddart RA, Burgess EF, Fleming MT, Rezazadeh Kalebasty A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Akapame S, Santiago-Walker AE, Monga M, O'Hagan A, Loriot Y; BLC2001 Study Group. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncol. 2022 Feb;23(2):248-258. doi: 10.1016/S1470-2045(21)00660-4. Epub 2022 Jan 11.
- Dosne AG, Valade E, Goeyvaerts N, De Porre P, Avadhani A, O'Hagan A, Li LY, Ouellet D, Perez Ruixo JJ. Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma. Cancer Chemother Pharmacol. 2022 Feb;89(2):151-164. doi: 10.1007/s00280-021-04381-4. Epub 2022 Jan 3.
- Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, Siefker-Radtke AO; BLC2001 Study Group. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2019 Jul 25;381(4):338-348. doi: 10.1056/NEJMoa1817323.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimado)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CR105065
- 2014 (Subvención/contrato del NIH de EE. UU.)
- 42756493BLC2001 (Otro identificador: Janssen Research & Development, LLC)
- 2014-002408-26 (Número EudraCT)
- 2023-510273-34-00 (Identificador de registro: EUCT number)
- 2023 (Subvención/contrato del NIH de EE. UU.)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .